19 November 2023
This study has analysed the transcriptomic and immune-metabolic profiles of Dendritic Cells (DCs) from 35 subjects enrolled in a trial of Dendritic Cells (DC) vaccines in late-stage melanoma. The authors conclude that the metabolic profile of DC is tightly associated with the immunostimulatory potential of DC vaccines from cancer patients, and they link phenotypic and functional metabolic changes to immune signatures that correspond to suppressed DC differentiation.
19 November 2023
According to this recent study, LAG3 inhibition for treating metastatic or unresectable melanoma has a reduced efficacy in patients with type 2 diabetes, possibly due to a low expression of LAG3 in tumor tissue.
17 November 2023
The purpose of this recent study was to compare the trends in incidence rates of cutaneous squamous cell carcinoma (cSCC) and melanoma, to provide insights into changing patterns of exposure to ultraviolet radiation. The study concludes that despite concerted international efforts to preserve the ozone layer over the past four decades resulting in significant reductions in surface UV-B at mid-latitudes, the incidence of skin cancer, particularly cSCC, continues to rise in those regions.
17 November 2023
Authors of this recent study conducted comprehensive analyses of melanoma metastases using bulk and single-cell RNA sequencing data, enabling the construction of a metastasis score (MET score) through diverse machine-learning algorithms.The study concludes that the MET score is effective in predicting melanoma metastatic potential. For patients with low MET scores, a PD-1 therapy may be a potential treatment strategy to inhibit metastasis. Patients with high MET scores may benefit from combination therapies.
17 November 2023
According to this recent study, use of combined therapeutic strategies triggering different apoptotic pathways may efficiently prevent the outgrowth of drug-resistant and -sensitive BRAF-mutant melanoma cells.
17 November 2023
According to this recent 20-year single-institution study of non-melanoma skin cancers (NMSCs), in order to improve prevention strategies and prevent further increases in the incidence, there is a need to develop current and exact registries of these malignancies, especially separately for the most common types – BCC and SCC.
15 November 2023
The aim of this recent study was to assess compliance of melanoma diagnosis and treatment timeliness with the MelNet Quality Statements at Waikato Hospital and in primary care for melanoma and melanoma in situ (MIS). The studu concludes that for 43 melanomas and 105 MIS, compliance across all melanoma services was poor, except for teledermatology response rates (100% compliance). From referral to first cancer treatment (Statement 2.1.1), compliance was 50% in general practice and 7.7% in Waikato Hospital. Histopathological reporting delays were also identified.
9 November 2023
The Cancer Society of New Zealand (Te Kāhui Matepukupuku o Aotearoa) has announced that the 2024 National Grant Round is now open. The aim of the National Grant Round is to fund high-quality research across the cancer continuum (including prevention, diagnosis, treatment, and supportive care). Specific funding is available for Melanoma research, and the Cancer Society encourage applications in this research area.
19 October 2023
RELATIVITY-020 studied the safety of nivolumab and relatlimab in patients whose disease progressed on anti-PD-(L)1 treatments. The study concludes that nivolumab and relatlimab had a manageable safety profile and demonstrated durable clinical activity in a proportion of patients with heavily pretreated advanced melanoma with prior progression on anti–PD-(L)1-containing regimens.
19 October 2023
According to this recent study, personalized and tumor-informed longitudinal circulating tumor DNA (ctDNA) monitoring is a valuable prognostic and predictive tool that may be used throughout the clinical course of patients with advanced melanoma.
